Description

Mycophenolate Sodium is an immunosuppressive agent used in scientific research to explore mechanisms of T- and B-cell proliferation inhibition, particularly in transplant immunology models and autoimmune disease studies.

This enteric-coated formulation by Chengdu Shengdi Pharmaceutical Co., Ltd. provides 0.18g of mycophenolate sodium per tablet, designed to ensure gastric bypass and targeted intestinal absorption, enhancing its reliability in pharmacokinetic and immunosuppressive studies.

This product is suitable for research labs requiring high-purity immunosuppressive materials. It meets NMPA regulatory standards under approval number H20213232 and is identified by the drug code 86980435000106.

Note: Strictly for research use only. Not intended for human or veterinary consumption.

Mycophenolate Sodium Enteric-Coated Product Specifications

Mycophenolate Sodium Enteric-Coated Mechanism of Action & Research Applications

Mycophenolate sodium is hydrolyzed in vivo to mycophenolic acid (MPA), which inhibits inosine monophosphate dehydrogenase (IMPDH). This action suppresses de novo purine synthesis, affecting lymphocyte proliferation.

Research Applications include:

• Organ transplantation immunosuppression models

• Autoimmune disease models (e.g., lupus, IBD)

• In vitro lymphocyte proliferation studies

• Pharmacokinetics and bioavailability trials

Mycophenolate Sodium Enteric-Coated Side Effects (For Reference Only in Models)

In research models, mycophenolate sodium may induce:

• Gastrointestinal disturbances

• Leukopenia or immunosuppression

• Hepatic enzyme alterations

• Teratogenic effects in developmental assays

Disclaimer

This product is intended solely for laboratory and experimental research. It is not intended for human or veterinary use. All research should follow institutional and national safety regulations.